CBS 2019
CBSMD教育中心
中 文

急性冠脉综合征

Abstract

Recommended Article

Nonsystem reasons for delay in door-to-balloon time and associated in-hospital mortality: a report from the National Cardiovascular Data Registry High-Sensitivity Troponins and Outcomes After Myocardial Infarction Management of Acute Myocardial Infarction During the COVID-19 Pandemic China PEACE risk estimation tool for in-hospital death from acute myocardial infarction: an early risk classification tree for decisions about fibrinolytic therapy How Will the Transition to hs-cTn Affect the Diagnosis of Type 1 and 2 MI? Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or with Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights from the AUGUSTUS Trial A Randomized Trial of a 1-Hour Troponin T Protocol in Suspected Acute Coronary Syndromes: The Rapid Assessment of Possible ACS In the Emergency Department with High Sensitivity Troponin T (RAPID-TnT) Study Fourth Universal Definition of Myocardial Infarction (2018)

Original Research

JOURNAL:CBS2017 Article Link

CBS Insight with Professor Yaling Han

CBS2017 Keywords: CBS Insight; Yaling Han; NeoVas; PSP

CBS Insight interviewed Prof Yaling Han at CBS2017



Biography

Prof. Yaling Han, renowned interventional cardiologist, Academician of Chinese Academy of Engineering since 2013, Director of Institute for Cardiovascular Diseases of PLA, Director of the Key Laboratory of Acute and Severe Cardiovascular Disease of PLA, Director of Cardiology Department of Shenyang Military Region, as well as the President of Chinese College of Cardiovascular Physicians (CCCP), elected Chairperson of Chinese Society of Cardiology (CSC), FACC, FESC. Editor-In-Chief of Chinese Journal of Cadiology, JACC International Advisors, Editorial board of Circulation and the Associate editor of Cardiovascular Therapeutics, Chairperson of Great Wall International Congress of Cardiology (GW-ICC) 2017, Vice Chairperson of Transcatheter Cardiovascular Therapeutics (TCT), Chairperson of Northeast Cardiovascular Forum (NCF). Prof. Han’s major academic contributions and technical expertise are interventional treatment and antithrombotic therapy of complex critical ischemic heart diseases. As principle investigator, prof. Han has led BRIGHT, TRACK-D, I-Love-It 2, CREATE, and other multi-center, large-scale clinical researches, and participated and exchanged her research outcomes at ACC, ESC, TCT, and other important international academic conferences. As first author, prof. Han has obtained 2 items of “Second Class Prize of National Scientific and Technological Progress” and 6 items of “First Class Prize of Military and Liaoning Province”. As corresponding author, Prof. Han has published more than 700 research papers, including the international journals JAMA, JACC, etc.



Reference used in this interview


A randomized trial comparing a novel sirolimus-eluting bioresorbable scaffold with everolimus-eluting metallic stents in patients with coronary artery disease



Remarks


Date of this Interview: Dec 1st, 2017

This video is intended for professional use only by physicians and is not intented for reposting or redistribution on other external channels.

Caution: This product is intended for use by or under the direction of a physician. Prior to use, reference CBS2017.

www.cbs2017.org. All rights reserved.